GLP-1 highs and lows continue in US for Novo Nordisk
Because Novo Nordisk competes directly with compounding pharmacies in the semaglutide market it has statutory and Article III standing to assert false advertising, a US judge ruled Monday. The win follows...To view the full article, register now.
Already a subscriber? Click here to view full article